Semaglutide 7.2 mg beats 2.4 mg for weight loss in STEP UP trial

A once-weekly 7.2 mg dose of semaglutide produced more weight loss than the 2.4 mg dose used for obesity, according to results of a phase 3b trial called STEP UP published September 14, 2025, in The Lancet Diabetes & Endocrinology ^[1]. Adults with obesity on the higher dose lost an average of 18.7% of their body weight, compared with 15.6% on 2.4 mg ^[1].

The trial reported weight loss two ways, a common practice in modern obesity studies. Under the treatment policy estimand, which counts every participant as originally assigned, including those who stopped taking the drug, average weight loss was 18.7% with 7.2 mg versus 15.6% with 2.4 mg ^[1]. Under the trial product estimand, which reflects results while participants stayed on their assigned treatment, the 7.2 mg dose produced 20.7% weight loss ^[1]. The two figures answer different questions: how the drug performed in the whole group as assigned, and how it performed among those who kept taking it ^[1]. The trial was randomized and controlled, and enrolled adults with obesity ^[1].

The higher dose also came with more side effects. Nausea was more common with 7.2 mg than with 2.4 mg, and dysesthesia, a term for abnormal sensations such as tingling or burning, was also more common at the higher dose ^[1]. The specific rates of each side effect at each dose have not been reported.

Several basic details have not been reported: how many people enrolled, how long the trial ran, how many participants stopped treatment, and whether the weight loss was maintained after treatment ended. Whether the dysesthesia cases were temporary or lasting also has not been reported. The 7.2 mg dose is investigational. It is not approved for any use, and no US regulatory filing for it has been disclosed.

Semaglutide is the molecule in Ozempic, Wegovy and Rybelsus. The 2.4 mg weekly dose used as the comparison in STEP UP is the strength approved for chronic weight management in the US.

Why it matters for patients

People taking semaglutide for obesity currently have a 2.4 mg weekly option and no higher approved dose in that product line. A 7.2 mg version would be a larger step rather than a different drug, and in this trial it came with more nausea and more dysesthesia ^[1]. That trade-off is the practical point: the extra weight loss measured in STEP UP was not free, and the trial reports averages, not individual outcomes. Some participants likely lost more than the average and some less, and the range of individual weight loss has not been reported.

Nothing changes for anyone now taking semaglutide. The 7.2 mg dose cannot be prescribed, and no data have been reported on what happens when patients move from 2.4 mg to 7.2 mg, or back down again. Cost and insurance coverage for a higher dose have not been disclosed either, and any new strength would need its own coverage decisions. How a higher dose would compare with switching to a different drug has not been studied in this trial.

What happens next

No dated milestones are attached to the 7.2 mg dose. Whether the manufacturer will ask the FDA to approve it, and when, has not been disclosed. Longer-term results, including whether weight loss is sustained and whether the dysesthesia finding changes over time, have not been reported.